Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

IPO Watch: The company combining cancer diagnostics and therapeutics with copper

  • In News
  • August 25, 2021
  • The Sentiment
IPO Watch: The company combining cancer diagnostics and therapeutics with copper

The complex nature of cancer means that scientists are having to get creative to improve diagnosis and treatment. Experts in the field of oncology ‘theranostics’ (combined therapeutic and diagnostic solutions), Clarity Pharmaceuticals (ASX: CU6) is due to make it’s ASX debut today.

Clarity has raised $92 million at $1.40 per share. Upon listing their indicative market cap will be $358.6 million.

The Australian based clinical-stage radiopharmaceutical company is working to develop products for use in diagnosis and therapy of cancers affecting both children and adults. Their proprietary SAR technology uses copper radioisotopes to deliver superior imaging and precision therapy.

Founded in 2010, the Company integrated licenses of intellectual property from The University of Melbourne and the Australian Nuclear Science and Technology Organisation to develop their platform.

The Company’s first clinical product, SARTATE began Phase 1 trials in 2015, successfully demonstrating its ability to target and better visualise cancer. Following diagnostic trial success, SARTATE entered into a therapeutics focused trial in children with neuroblastoma, an aggressive childhood cancer of immature nerve tissue. Promising results in this area of cancer treatment formed the basis for Clarity’s targeted copper theranostics (TCT) SAR platform.

Clarity’s science is built around copper isotopes which they link to a target molecule via chelators. Chelators act as cages to retain copper isotopes to prevent their leakage into the body. The target molecule finds and binds to tumour specific receptors on the surface of cancer cells. Having found the cancer cell, the linked copper isotope acts as a beacon, allowing for specialised imaging machines to pinpoint the exact location of cancer cells.

The copper isotope also enables treatment of the disease by targeting and killing specific cancer cells through radiation.

This isn’t a new concept. Radioisotopes are an essential part of many medical diagnostic procedures, with physicians in the 1950s using nuclear medicine to diagnose and treat conditions such as thyroid disease. The use of radioisotopes in therapy is however, a relatively new concept and is primarily being looked at for the treatment of malignancies.

Whilst numerous cancer therapies do exist, there are many undeniably and overwhelmingly negative side effects stemming from blasting the entire body with chemotherapy drugs or radiation. Targeted, sophisticated therapies are the next phase of fine tuning our response to cancer.

Additional products are now in Clarity’s pipeline: SAR-Bombesin and SARbisPSMA, for management and treatment of breast and prostate cancers. These drugs are progressing through Phase 1 studies. The Company is aiming to target the lucrative US market for first product approvals.

Given the complexities of cancer and the vigorous approval process for drugs as well as their lack of profitability means an investment in Clarity does carry a considerable amount of risk, but with upside to potentially disrupt the USD $5.9 billion radiotherapy market.

  • About
  • Latest Posts
The Sentiment
The Sentiment – a source of news and opinion shaping public sentiment on ASX-listed companies.
Latest posts by The Sentiment (see all)
  • IG study shows ASX traders most bullish since January 2022 - April 24, 2024
  • Share prices to rise after debt ceiling deal - May 29, 2023
  • Why invest in Australian Stocks over American Stocks? - April 21, 2023
  •  
  •  
  •  
  •  
  • chelators
  • clarity pharmaceuticals
  • IPO
  • radiopharmaceuticals
  • theranostics
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
The Sentiment
The Sentiment – a source of news and opinion shaping public sentiment on ASX-listed companies.
Latest posts by The Sentiment (see all)
  • IG study shows ASX traders most bullish since January 2022 - April 24, 2024
  • Share prices to rise after debt ceiling deal - May 29, 2023
  • Why invest in Australian Stocks over American Stocks? - April 21, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
The Sentiment
The Sentiment – a source of news and opinion shaping public sentiment on ASX-listed companies.
Latest posts by The Sentiment (see all)
  • IG study shows ASX traders most bullish since January 2022 - April 24, 2024
  • Share prices to rise after debt ceiling deal - May 29, 2023
  • Why invest in Australian Stocks over American Stocks? - April 21, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.